Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline Review uri icon

Overview

MeSH Major

  • Neoplasms, Glandular and Epithelial
  • Ovarian Neoplasms

abstract

  • All women with suspected stage IIIC or IV invasive epithelial ovarian cancer should be evaluated by a gynecologic oncologist prior to initiation of therapy. The primary clinical evaluation should include a CT of the abdomen and pelvis, and chest imaging (CT preferred). Women with a high perioperative risk profile or a low likelihood of achieving cytoreduction to < 1 cm of residual disease (ideally to no visible disease) should receive neoadjuvant chemotherapy. Women who are fit for primary cytoreductive surgery, and with potentially resectable disease, may receive either neoadjuvant chemotherapy or primary cytoreductive surgery. However, primary cytoreductive surgery is preferred if there is a high likelihood of achieving cytoreduction to < 1 cm (ideally to no visible disease) with acceptable morbidity. Before neoadjuvant chemotherapy is delivered, all patients should have confirmation of an invasive ovarian, fallopian tube, or peritoneal cancer. Additional information is available at www.asco.org/NACT-ovarian-guideline and www.asco.org/guidelineswiki.

publication date

  • October 2016

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC5512594

Digital Object Identifier (DOI)

  • 10.1200/JCO.2016.68.6907

PubMed ID

  • 27502591

Additional Document Info

start page

  • 3460

end page

  • 73

volume

  • 34

number

  • 28